AmpliMed Corporation, a privately held, early stage biotechnology company, originated as a group of research projects within the Arizona Cancer Center (AZCC), part of the University of Arizona. In 1989 it became a separate company and focused on the development of therapeutic agents for high value oncology indications. AmpliMed, utilizing the research facilities at AZCC, operates as a virtual company with flexible expense margins. It currently has two lead oncology drug candidates, Imexon and AMP-53, in it's product pipeline. In April 2003 AmpliMed received an IND approval from the FDA for Imexon, a cyanoaziridine series compound. AmpliMed is now moving this drug candidate into clinical development at AZCC.

Click Here to contact us about the AmpliMed Corporation.

InvestBio structures institutional quality investment opportunities for the qualified individual investor. Our scientific advisors have access to valuable industry insights, allowing us to identify the most promising research and drugs. We structure an investment partnership for our clients and typically invest side-by-side, at the same price and timing, in targeted private equity investments. This approach allows our interests to be directly aligned with our investors. On Wall Street, these investment opportunities are often only accessible to institutional investors, however, we at InvestBio believe that these opportunities should also be available to the qualified individual investor. We make that happen. InvestBio is a wholly owned subsidiary of DPEC Partners.